BMY vs EBS · P/E 17, rev $48.19B vs rev $1.04B
Bristol-Myers Squibb Company (BMY) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BMY revenue for 2025-12-31 was $48.19B. Net income was $7.05B. Revenue was down 0.2% from 2024-12-31 to 2025-12-31. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. EBS currently screens at market cap $416.4M.
Not investment advice. Open the BMY and EBS stock pages for the full models.
Not investment advice.